论文部分内容阅读
目的探讨甲氨蝶呤联合米非司酮治疗异位妊娠的临床疗效和安全性。方法选取2011年1月~2014年4月该院收治的96例异位妊娠患者为研究对象,随机分为对照组和观察组,每组各48例。对照组给予甲氨蝶呤治疗,观察组在对照组治疗基础上联合应用米非司酮治疗,疗程均为2周。比较两组患者治疗前后血清β-h CG值、包块大小、血孕酮值变化、临床效果和不良反应情况。结果观察组患者总有效率明显高于对照组,差异有统计学意义(χ2=8.161,P=0.017)。治疗前,两组间血β-h CG、包块大小、血孕酮水平比较,差异均无统计学意义(P均>0.05);治疗后,两组患者的血β-h CG、包块大小、血孕酮水平较治疗前相比均明显降低,差异均有统计学意义(P均<0.05);而且观察组下降较对照组更为明显,两组比较,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论甲氨蝶呤联合米非司酮治疗异位妊娠临床效果显著,安全性好,值得在临床推广应用。
Objective To investigate the clinical efficacy and safety of methotrexate combined with mifepristone in the treatment of ectopic pregnancy. Methods Ninety-six patients with ectopic pregnancy admitted to our hospital from January 2011 to April 2014 were selected as study subjects and randomly divided into control group and observation group, 48 cases in each group. The control group was treated with methotrexate. The observation group was treated with mifepristone on the basis of the control group, and the course of treatment was 2 weeks. The changes of serum β-h CG, mass size, blood progesterone, clinical effects and adverse reactions were compared between the two groups before and after treatment. Results The total effective rate of the observation group was significantly higher than that of the control group, the difference was statistically significant (χ2 = 8.161, P = 0.017). Before treatment, blood β-h CG, mass size and blood progesterone level were not significantly different between the two groups (all P> 0.05). After treatment, β-h CG, The level of blood progesterone were significantly lower than those before treatment, the differences were statistically significant (P <0.05), and the observation group decreased more significantly than the control group, the difference between the two groups was statistically significant (P <0.05). The incidence of adverse reactions in the two groups, the difference was not statistically significant (P> 0.05). Conclusion Methotrexate combined with mifepristone treatment of ectopic pregnancy clinically significant, safe, it is worth in the clinical application.